The EPS miss is notable but typical for a pre-revenue biotech; the stock will likely trade on pipeline catalysts. Watch for Phase 3 trial initiation and any financing updates given the $10.7M cash runway (estimated ~9 months at current burn).
Price Chart
Executive Summary
Acurx Pharmaceuticals reported Q2 2026 EPS of -$0.53, a 26% miss versus the $0.42 consensus, reflecting higher R&D spending. The company highlighted positive FDA guidance for a single Phase 3 trial for ibezapolstat and new patent grants, but the EPS miss and pre-revenue status keep the stock under pressure.
Key Financial Metrics
Key Facts
- Q2 2026 net loss of $2.3M ($0.53 per share) vs consensus of $0.42 loss per share (26% miss)
- Cash position improved to $10.7M from $7.6M at year-end 2025, aided by $2.5M registered direct offering and $0.8M from equity line
- R&D expenses rose to $1.1M (vs $0.5M a year ago) due to manufacturing and consulting costs for the recurrent CDI trial
- FDA provided guidance supporting a single Phase 3 study as a pivotal trial for ibezapolstat NDA filing
- New patents granted in Japan and Mexico for DNA pol IIIC inhibitors, expanding international IP portfolio
Financial Impact
EPS miss of $0.11 per share (26% below consensus); cash burn rate ~$1.2M/month based on Q2 operating expenses
Risk Factors
- Cash runway may require additional financing before Phase 3 data readout
- Phase 3 trial execution and regulatory approval risks for ibezapolstat
- Dilution risk from outstanding warrants (1.65M shares) and equity line of credit
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-prn-302850984 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 18, 2026 5w ago | EFFECT | $1.39 $1.10 | ▲ +20.86% | ▲ +21.07% | $1.13 (+18.35%) |
Aug 14, 2026 10w ago | Press Release | $1.40 $1.39 | ▼ −0.36% | ▲ +1.63% | $1.13 (−18.64%) |
May 4, 2026 25w ago | S-1 | $2.00 $1.80 | ▲ +10.00% | ▲ +14.95% | $1.13 (+43.25%) |
May 4, 2026 25w ago | S-1 | $2.00 $1.80 | ▲ +10.00% | ▲ +14.95% | $1.13 (+43.25%) |
Apr 16, 2026 27w ago | 8-K | $2.49 $1.99 | ▼ −20.08% | ▼ −25.90% | $1.13 (−54.42%) |
Apr 16, 2026 27w ago | 424B5 | $2.49 $1.99 | ▲ +20.08% | ▲ +25.90% | $1.13 (+54.42%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers